A second phase 3 clinical trial of Eyenovia’s MicroStat fixed-combination formulation showed positive results and met its primary endpoint, according to a press release.
The MIST-2 multicenter, randomized, double-masked, superiority trial included 70 subjects treated with the MicroStat fixed combination formulation of phenylephrine 2.5% and tropicamide 1% administered using Eyenovia’s piezo-print delivery Optejet dispenser. It was compared with placebo, which was also delivered via the Optejet dispenser.
The MicroStat group was clinically and statistically superior in terms of
Uncategorized